| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-09 | Press release | 07-09-2026 - ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months |
| 2026-07-09 | 8-K | Form 8-K, Item 2.02 results |
| 2026-06-17 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-12 | Deck | Introduction to ImmuCell Investor Presentation |
| 2026-06-11 | Proxy | Proxy Statement · FY 2025 |
| 2026-06-10 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-07 | Document | Managing Passive Transfer Variability at Calf Ranches: Effects of Hyperimmunized Bovine Colostrum Supplementation on Hea |
| 2026-06-07 | Document | First Defense Technology® Field Demonstration Summary of a field demonstration to evaluate the impact of a First Defense |
| 2026-05-15 | Document | Key reasons IgY paste/gel products do not provide lasting immune support to calves |
| 2026-05-15 | Deck | Earnings Presentation · Q1 2026 |
| 2026-05-15 | Deck | Investor presentation · Q2 2026 · May 2026 |
| 2026-05-14 | Press release | 05-14-2026 - ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026 |
| 2026-05-14 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-14 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-13 | 10-K | Annual report on Form 10-K/A, FY25 |
| 2026-05-08 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-07 | Press release | 05-07-26 - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026 |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-14 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-13 | Press release | 04-13-26 - ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors |
| 2026-04-08 | Press release | 04-08-26 – ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results |
| 2026-04-08 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-30 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-18 | Press release | 03-18-26 ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board |
| 2026-03-18 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-06 | Transcript | Q4 FY25 earnings call transcript |
| 2026-03-04 | Press release | 03-04-26 ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025 |
| 2026-03-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-23 | Document | Hyperimmune colostrum: taking nature’s most powerful defense to the next level |
| 2026-02-18 | Press release | 02-18-26 ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 |
| 2026-02-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-01-19 | Document | Maternity barn: setting the stage for healthy beginnings |
| 2026-01-08 | Press release | 01-08-26 ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 |
| 2026-01-08 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-07 | Press release | 01-07-26 ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus · Q4 2025 |
| 2026-01-05 | Document | A veterinarian’s perspective on the safety of precalving scours vaccines |
| 2025-12-29 | Document | Sick calves - where did I trip up? |